New Treatment Option for Non-Hodgkin Lymphoma Delays Tumour Progression With ... MarketWatch (press release) A trial that enrolled 549 patients with certain types of immune system cancers showed that bendamustine and rituximab worked better and was less toxic than standard treatment. Patients treated with bendamustine and rituximab lived more than three years ... 'Rediscovered' lymphoma drug helps double survival: study |
